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ABSTRACT   1 
Introduction: Stage Ta bladder cancer (TaBC) accounts for around half of all new cases of 2 
urothelial bladder cancer (UBC), and displays a heterogeneous behavior with 5 yr recurrence 3 
rates which vary from 31% to 78%, whilst progression ranges from 0.8% to 45%. Optimal 4 
management is crucial to achieve safe yet economical long-term outcomes. The purpose of this 5 
paper is to provide an overview of such management. 6 
Methods: Using American Urological Association, National Comprehensive Cancer Network 7 
(NCCN), European Association of Urology (EAU) and the International Consultation on 8 
Urological Diseases-EAU (ICUD-EAU) guidelines as the basis of this non-systematic review, we 9 
utilized PubMed searches to update the literature in this field, and to expand upon topics of 10 
particular interest or controversy. 11 
Results: We have provided an overview for the practicing urologist of the safe and economical 12 
care of TaBC with regard to risk stratification, pre- and peri-operative care, subsequent 13 
adjuvant treatment, surveillance, management of recurrences and long-term outcomes. Whilst 14 
these recommendations are already incorporated within current guidelines, some aspects 15 
deserve further discussion or have been the subject of relevant research subsequent to 16 
guideline publication. 17 
Conclusions: The traditional view that TaBC is invariably synonymous with low risk disease 18 
requires re-evaluation. Modern management of TaBC depends on initial risk stratification that 19 
allows subsequent management based on a number of evidence-based guidelines. Given the 20 
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usual long clinical course of TaBC, such an approach ensures not only safe but economical care 21 
of this group of patients. 22 
23 
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INTRODUCTION 24 
Urothelial bladder cancer (UBC) is the fifth most common cancer in Western societies, 25 
accounting for 69,000 and 180,000 new cases per year in the USA and EU 1, respectively. 26 
Emerging patterns of cigarette smoking and occupational carcinogen exposure mean that the 27 
incidence of UBC is rising globally 2. However, there has been little improvement in the 28 
outcome for patients with UBC since the 1980s 3,4, possibly reflecting complex patient pathways 29 
and treatments, combined with a lack of therapeutic advances 4. 30 
As a result of the chronic clinical course of non-muscle-invasive bladder cancer (NMIBC), its 31 
prevalence relative to muscle-invasive disease (MIBC), and the risks of recurrence and 32 
progression that necessitate long-term cystoscopic surveillance and frequent interventions, the 33 
associated cumulative costs of NMIBC are considered to be greater than those for MIBC 5, 6. It is 34 
also evident that the care for patients with NMIBC cancer varies considerably both by region 7 35 
and by physician 8. Indeed, the latter has been shown to have more influence over the cost of 36 
NMIBC care than the stage and grade of the disease itself 9.  37 
Stage Ta bladder cancer (TaBC) is defined as a non-invasive papillary carcinoma of the bladder10 38 
and accounts for 48-53% of all new cases of UBC 11,12, a proportion that has remained stable for 39 
20 years 11,13. TaBC displays a heterogeneous behavior with 5 yr recurrence rates which vary 40 
from 31% for a solitary <3cm G1pTa to 78% for a recurrent > 3cm multifocal G3pTa with 41 
carcinoma in situ (CIS), whilst progression for the same tumours ranges from 0.8% to 45%, 42 
respectively 10. Although conventionally patients with TaBC have been labeled as ‘low-risk’ non-43 
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muscle invasive bladder cancer (LR NMIBC), 30% have high grade or G3 disease 13 and over 11% 44 
of patients will progress and may eventually die from bladder cancer 14,15.  There is therefore a 45 
need to stratify TaBC patients for optimal management. 46 
The aim of this review is to provide an overview of the safe and economical management of 47 
patients with TaBC, and based upon a validated risk stratification scheme such as that proposed 48 
by the EAU Guidelines on NMIBC 10. 49 
50 
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METHODS 51 
This is a non-systematic review specifically focusing on issues relating to TaBC. AUA, NCCN, EAU 52 
and ICUD-EAU guidelines were reviewed 16,17,18, along with papers obtained following PubMed 53 
searches of relevant search terms to take account of more recent evidence in this field. These 54 
were used by the authors, in conjunction with their consensus opinion as experienced 55 
urologists, to produce a review of the safe and economical care of TaBC. Detailed economic 56 
assessments of UBC practice have been undertaken recently, exemplified by 6 and 19, and 57 
have been incorporated into our consensus opinion; recapitulating such analyses was 58 
considered to be beyond the scope of this review, especially given their significant 59 
geographical variation as illustrated in Table 1. 60 
61 
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DEFINING NMIBC RISK CATEGORIES 62 
In 2006 The European Organisation for Research and Treatment of Cancer (EORTC) published 63 
risk tables to predict recurrence and progression in individual patients based on an algorithm 64 
utilising a number of clinical and pathological factors: tumor number, tumor size, prior 65 
recurrence rate, T stage, presence or absence of CIS, and grade 20.  The tables were based on an 66 
analysis of data from historical trials, although other studies have suggested that when used as 67 
part of modern NMIBC management they overestimate recurrence and progression 21. 68 
However, to date, there is no better risk categorization tool. 69 
Originally intended to be used as an aid to discussing treatment options with patients, they 70 
were subsequently used by the EAU NMIBC guidelines committee as the basis for their 71 
recommendation to categorize NMIBC into low, intermediate and high risk 10: 72 
 Low-risk tumors: Primary, solitary, Ta, low grade/G1, <3 cm, no CIS. 73 
 High-risk tumors: Any of the following - T1 tumor, high grade/G3 tumor, CIS and 74 
specifically recurrent multiple >3 cm Ta G1/2 tumors  75 
 Intermediate-risk tumors: All other tumours 76 
Although the concept of high-risk NMIBC has been in use for some time, it is no longer 77 
appropriate to consider all other NMIBCs as a single homogeneous group and the use of risk 78 
categorization should be considered an essential first step in the safe management of all 79 
TaBC. In addition, there is a need to recognise a state of progression prior to muscle-invasion 80 
8 
 
 
such that a tumor’s behavior can be appropriately characterized and managed. Therefore, the 81 
concept of ‘biological progression’ has recently been defined by the International Bladder 82 
Cancer Group as: an increase in T stage from CIS or Ta to T1, development of T2 or greater or 83 
lymph node (N+) disease or distant metastasis (M1), or an increase in grade from low to high 22.84 
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 85 
PRE-OPERATIVE CARE 86 
Urine Cytology and Urinary Markers 87 
Following initial identification of a papillary bladder tumor, additional urine cytology and 88 
urinary markers are of limited value in the preoperative management of TaBC 18 since they are 89 
unlikely to alter subsequent surgical management. However, they may have an important role 90 
during follow-up, as discussed below. 91 
 92 
Upper Tract Studies 93 
The incidence of synchronous upper tract urothelial carcinoma (UTUC) is unclear but is likely to 94 
be low since the incidence of metachronous UTUC in TaBC is very low (0.3%) 23. Nevertheless it 95 
has been suggested that multifocal NMIBC carries a higher risk of UTUC 24. All patients with UBC 96 
should have an ultrasound of the urinary tract as part of their initial investigations which is 97 
sufficient to identify significant upper tract disease such as renal cell carcinoma, stones and 98 
UTUC. Further imaging with computed tomography, magnetic resonance imaging or 99 
intravenous urogram in patients with TaBC specifically to identify synchronous UTUC carries 100 
additional risks and is not recommended 18. 101 
102 
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 PERI-OPERATIVE CARE 103 
Transurethral Resection 104 
The initial gold standard treatment of any suspected bladder tumor remains transurethral 105 
resection (TURBT) in order to allow complete removal and histological classification of the 106 
tumor including assessment of the depth of invasion 25. There is increasing evidence that the 107 
quality of the TURBT has a major impact on the recurrence rate 26 and that experienced 108 
urologists have lower recurrence rates than trainees 27. There has been recent interest in the 109 
use of visual aids at the time of TURBT such as blue light photodynamic diagnosis (PDD) or 110 
narrow band imaging (NBI). Two recent meta-analyses have confirmed a 20% increased 111 
tumour detection rate for PDD over white light cystoscopy alone 19,28, with the inference that 112 
detecting as many tumors as possible at the time of initial TURBT reduces the recurrence rate 113 
at the first check cystoscopy . However, despite an improved initial detection rate, this has 114 
not translated into improvements in long-term recurrence rates when compared to white 115 
light 29. Therefore, at the present time, there is no compelling evidence that using PDD or NBI 116 
results in better outcomes for patients with TaBC. 117 
 118 
Immediate Intravesical Chemotherapy  119 
A single dose of intravesical chemotherapy (IVT) within 24 hours of TURBT has been shown to 120 
reduce the odds of recurrence by 39% 30. Although recent studies have questioned the value of 121 
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such a policy for all patients, the value of preventing small recurrences has been confirmed 31. 122 
Since even the most favorable prognosis TaBC patients will have a 5 year recurrence rate of 123 
31%, and whilst a study has shown 93% correlation between a visual diagnosis of a Ta tumor 124 
and histology 32, it would seem reasonable to offer all patients with apparent TaBC a single 125 
instillation of IVT at first presentation. Unfortunately, according to a recent survey, the uptake 126 
of a single instillation of IVT is low in the US with only 16.9% of eligible patients receiving IVT, 127 
whilst 66% of those surveyed never offered it 33. One barrier to more widespread adoption of 128 
immediate peri-operative IVT may be the difficulties of ensuring timely instillation by 129 
appropriately trained personnel in operating theatres or wards. This may be overcome by 130 
administration of the IVT by the operating urologist at the end of TURBT, which is considered 131 
safe 34. 132 
133 
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FURTHER MANAGEMENT 134 
Early Re-Staging TURBT 135 
All patients with high-risk TaBC should undergo an early re-staging TURBT within 4-6 weeks - 136 
this has been shown to identify and remove residual tumour as well ensuring that understaging 137 
of MIBC has not occurred 17,18,35,36. In low-risk TaBC, a re-staging TURBT should only be 138 
considered when there is doubt about the completeness of the original TURBT 10. 139 
 140 
Adjuvant Intravesical therapy 141 
The need for further adjuvant therapy in patients with TaBC will depend on their stratification 142 
as low-, intermediate or high-risk Ta tumors as defined above by the EAU 10. 143 
Low-risk Ta 144 
These tumors make up 50-70% of all TaBCs 13. Apart from a single instillation of IVT immediately 145 
following TURBT, as discussed above, no further adjuvant treatment is indicated in this group 146 
10,17,18.   147 
High-risk Ta 148 
These tumors make up 20-30% of all TaBCs 13. Such patients require an induction course of BCG 149 
followed by a minimum of 1-3 years of maintenance BCG in order to reduce the risk of 150 
recurrence 10. The effect of BCG on progression is less clear 18,37.  151 
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Intermediate-risk Ta 152 
The EAU guidelines alone describe these as a separate and distinct group. In order to reduce 153 
the risk of recurrence the EAU guidelines recommend one immediate instillation of IVT 154 
followed by 1 year full-dose BCG treatment, or by further instillation of IVT for a maximum of 1 155 
year 10. 156 
157 
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SURVEILLANCE  158 
Cystoscopy 159 
In order to mitigate the risks of recurrence and progression described above, the safe long-160 
term management of TaBC is founded upon diligent cystoscopic surveillance. The first 161 
cystoscopy after TURBT at 3 months is considered a key prognostic indicator for recurrence and 162 
progression 38. For subsequent surveillance the EAU, NCCN and AUA guidelines show disparity, 163 
with the NCCN and AUA guidelines being less specific 6. The EAU guidelines take a risk-adapted 164 
approach 10:  165 
 For patients with low-risk tumors, the first surveillance cystoscopy should take place 3 166 
months following TURBT; if negative, the next cystoscopy should take place 9 months 167 
later, with surveillance continuing for 5 years.  168 
 Patients with high-risk tumors should undergo cystoscopy and cytology at 3 months 169 
following TURBT. If negative, subsequent cystoscopy and cytology should be repeated 170 
every 3 months for 2 years, every 6 months thereafter until 5 years, and then yearly. 171 
  Patients with intermediate-risk tumors should have an in-between follow-up scheme 172 
using cystoscopy and cytology, adapted according to personal and subjective factors. 173 
 In tumors originally intermediate- or high-risk, recurrences after 10 years tumor-free 174 
interval are not unusual. Therefore, lifelong follow-up is recommended. 175 
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NCCN guidelines state that patients with Ta low-grade tumors should  “undergo a cystoscopy 176 
at 3 months initially, and then at increasing intervals”, whilst Ta high-grade tumors should be 177 
followed up “with a urinary cytology and cystoscopy at 3-6 month intervals for the first 2 178 
years, and at increasing intervals as appropriate thereafter” 17. The AUA guidelines state that: 179 
“Although a variety of different follow-up strategies have been advocated, the most common 180 
approach has included patient assessment every three months in the first two years after initial 181 
diagnosis followed by every six months for the subsequent 2 to 3 years, and then annually 182 
thereafter. Clinical follow-up involves an appropriate patient history including voiding symptoms 183 
and hematuria, urinalysis, cystoscopy, and urine cytology” 16.  184 
Evidence in support of the risk-adapted approach originates over 20 years ago with economic 185 
benefits demonstrated 39. To our knowledge, formal health economic evaluations or 186 
randomized studies of varying schedules of surveillance have not been carried out since 10. 187 
Other aspects regarding the safe and economical management of TaBC require further 188 
discussion. Firstly, the EAU guidelines recommend a surveillance period of 5 years for low-risk 189 
NMIBCs if no recurrences are detected during surveillance 10. Given the long-term outcomes 190 
described above for TaBC, with a meaningful risk of death from bladder cancer, we suggest that 191 
surveillance should continue for at least 10 years for low-risk TaBC; other authors have recently 192 
made similar recommendations 15. Secondly, variation in treatment intensity does not impact 193 
survival or the avoidance of subsequent major interventions 9, so more intensive surveillance 194 
schedules than recommended should be avoided. However, the influence of “personal and 195 
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subjective factors” on NMIBC surveillance should not be underestimated 10. Despite the 196 
evidence-based guidelines above, clinicians know their patients best - all who work in this field 197 
appreciate the ‘feel’ that one gets for the behavior of a particular patient’s tumor during the 198 
course of years of surveillance. It is therefore difficult to criticize any urologist taking a 199 
personalized approach on a case-by-case basis, and especially in younger patients with a life-200 
expectancy of over 30 years. However, given these caveats, we feel that the risk-adapted 201 
approach of the EAU guidelines represents the most appropriate approach to NMIBC 202 
surveillance, and intuitively results in a cost benefit 6. 203 
 204 
Upper Tract Surveillance 205 
The EAU guidelines recommend annual upper tract imaging with CTU or IVU for patients with 206 
high-risk tumors, or if cytology is positive in the absence of visible tumour 10, whilst the AUA 207 
guidelines state that: “Surveillance often includes periodic upper tract imaging, especially for 208 
high-risk patients” 16. However, the supporting evidence for such an approach for patients with 209 
TaBC is unclear. Sternberg et al retrospectively reviewed the treatment and follow-up of 935 210 
NMIBC patients, from which 51 patients were subsequently diagnosed with UTUCs with a 211 
median follow-up of 5.5 years 40. The 5- and 10-year UTUC-free probabilities among patients 212 
with Ta tumors were 98% and 94% respectively 40. During the follow-up period, UTUC was 213 
diagnosed in 16 out of 481 patients with Ta NMIBC (3.3%): 10 (2.1%) after symptoms developed 214 
and only 4 (0.8%) on routine imaging (2 unknown, 0.4%) 40. The authors concluded that: “While 215 
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upper tract recurrence remains a lifelong risk for patients with bladder cancer, only a minority 216 
will be diagnosed on routine surveillance CT urography. The majority of UTUC can be diagnosed 217 
with a surveillance strategy including thorough history, physical examination, urine cytology, 218 
cystoscopy and renal sonography” 40. An optimal upper tract surveillance schedule is therefore 219 
yet to be defined for patients with TaBC, and further studies are needed.  220 
 221 
Cytology and Urinary Biomarkers 222 
Urine cytology is subjective and expensive, with low sensitivity (10-51%) yet high specificity (83-223 
96%) 19,41; it is this high specificity which makes it an attractive test. However, its role in the 224 
surveillance of low-risk Ta tumors has to be questioned, despite having an important role in the 225 
surveillance of intermediate- and high-risk Ta tumors 10.  226 
Accurate urinary biomarkers could theroretically reduce the frequency of cystoscopy for low- 227 
and intermediate-risk groups, thus reducing patient burden, improving quality of life, and 228 
reducing costs to healthcare providers. For patients with high-risk disease, urinary biomarkers 229 
could be utilized in-between surveillance cystoscopies, with positive results prompting rigid 230 
cystoscopy±TURBT, potentially reducing the risk of progression to MIBC during surveillance. 231 
Although a number of biomarkers are commercially available and FDA-approved, no single 232 
marker or test has yet demonstrated sufficient sensitivity and specificity to be acceptable to 233 
patients and clinicians, and to replace cystoscopy 19,42. For these reasons, the AUA guidelines 234 
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conclude that: “At the present time, the use and utility of urine-based molecular markers in the 235 
follow-up of patients remains uncertain” 16, and the EAU guidelines that: “No non-invasive 236 
method has been proposed that can replace endoscopy, therefore, follow-up is based on regular 237 
cystoscopy” 10. 238 
239 
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MANAGEMENT OF RECURRENCES  240 
Office Fulguration and TURBT 241 
Conventionally, recurrences are managed by TURBT in the operating theatre. Tumour is 242 
obtained for histopathological examination alongside biopsy material from any abnormal or 243 
suspicious areas of the urothelium. This represents the safest and most appropriate 244 
management of patients with intermediate- and high-risk TaBC. 245 
Whilst the absence of detrusor muscle (DM) in the resection specimen is associated with a 246 
higher incidence of residual disease and early recurrence, many recurrent TaBCs are small 247 
papillary lesions that are unlikely to involve the lamina propria and DM. In such cases a further 248 
deeper resection than needed to remove the tumor itself, simply to obtain DM, is 249 
unnecessary25,18.  250 
In many patients with recurrent low-risk TaBC, inpatient TURBT under general or regional 251 
anaesthesia may represent overtreatment. It is considered that these patients can be safely 252 
managed by fulguration/ablation in the office setting 43,44. This view is supported by the EAU 253 
guidelines which state: “Fulguration of small papillary recurrences on an outpatient basis could 254 
be a safe option that reduces the therapeutic burden” 10. However, the benefits of convenience 255 
and reduced cost and burden to the patient and clinician should be carefully considered 256 
against the risks of not undertaking histopathological examination of the lesion and 257 
potentially missing grade or stage progression. The balance of risk depends upon the 258 
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experience of the clinician and their ability to correctly identify low-risk TaBC macroscopically. 259 
Published data demonstrates that clinicians with a specialized bladder cancer interest can 260 
correctly prediction G1 pTa recurrences in 93-99% of patients 32, but outside of such settings 261 
the results are less favourable 45. We are therefore of the opinion that for the safe 262 
management of TaBC, office fulguration/ablation alone (without biopsy) may be an 263 
unsuitable approach for urologists without a specialized bladder cancer practice. Clearly, 264 
common sense should prevail, and office/outpatient fulguration/ablation may have wider 265 
applicability for very elderly or infirm patients with comorbidities.    266 
 267 
Active Surveillance 268 
The terms active surveillance (AS), observation, expectant management and watchful waiting 269 
are all used to describe cystoscopic monitoring of Ta recurrences. In specialized practices TaBC 270 
recurrences can be identified accurately in 93% of cases rising to 99% if urine cytology is also 271 
used 32. Their natural history is well known and is characterized by recurrences requiring 272 
repeated treatment, rather than by progression. The concept of AS was first described by 273 
Soloway 46 who observed progression in either stage or grade in 9% of TaBCs, whilst no patients 274 
developed MIBC. These findings have been confirmed by others 47,48, with grade progression 275 
ranging between 9-16% and stage progression ranging between 4.5-6%. AS requires a clear 276 
discussion between urologist and patient and may be particularly suitable for patients with 277 
significant comorbidity. Finally, AS lends itself to combination with office fulguration, and a 278 
21 
 
 
combination of approaches using AS with office biopsy and fulguration of recurrences, followed 279 
by an immediate instillation of IVT, may allow many TaBC patients to avoid inpatient TURBT 280 
(MS Soloway, personal communication) 18. 281 
 282 
Chemoresection in the Treatment of NMIBC 283 
Several small studies have shown promising results with complete ablation of small papillary 284 
tumours with intravesical chemotherapy alone (chemoresection), but the optimal schedule and 285 
the effectiveness of chemoresection for TaBC is unclear 49. Two reviews of chemoresection 286 
included over 1,200 patients in all three NMIBC risk groups and described a number of different 287 
chemotherapy agents given in 4-8 instillations. On average, complete response was 50%, with 288 
therapeutic effect sustained for at least 2 years 49,50. The National Institute of Health Research 289 
(UK) have recently funded a randomised trial of chemoresection versus standard surgical 290 
management of low-risk NMIBC (CALIBER trial) which should help define the role of 291 
chemoresection in TaBC.  292 
293 
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LONG-TERM OUTCOMES 294 
The long-term outcome from TaBC is worthy of particular mention. Wallace et al demonstrated 295 
that, when followed-up for over 8 years, 21% of patients who subsequently died following an 296 
initial diagnosis of TaBC were certified to have died from bladder cancer 14. Although this cohort 297 
of patients was recruited in 1991-2 (and treated according to UK practice at the time), these 298 
data would suggest that TaBC is perhaps a more significant disease in the long-term than 299 
generally considered. The ongoing follow-up of this cohort of patients (now over 18 years) 300 
substantiates this supposition (RT Bryan, unpublished data). 301 
302 
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DISCUSSION 303 
The AUA, NCCN, EAU and ICUD-EAU guidelines are excellent documents providing essential 304 
advice for the management of NMIBC 10,16,17,18, and are regularly and thoroughly updated by 305 
experts in the field. They therefore represent safe practice for the management of TaBC, and 306 
we have used these guidelines as the basis for this review. However, some aspects deserve 307 
further discussion or have been the subject of relevant research subsequent to guideline 308 
publication. In conjunction with our consensus opinion as experienced urologists in this field 309 
and whilst incorporating data from economic analyses 6,19, we have written this paper as a 310 
review of the safe and economical care of TaBC that is of most relevance to a clinical urological 311 
readership. This approach is summarized in Figure 1.  312 
The non-medical costs that are associated with UBC care, costs that are borne by patients, their 313 
families, and their employers, are huge 6, and there is a plethora of further research that is 314 
urgently required in this setting 4,6. For example, in the current era of enhanced optical 315 
modalities for cystoscopy it is feasible that a technology with increased sensitivity for detecting 316 
recurrences (such as NBI) may permit the intervals between surveillance cystoscopies to be 317 
lengthened for low- and intermediate-risk NMIBCs. Such approaches would clearly lead to 318 
economic benefits and reduced patient burden if equivalent outcomes to conventional 319 
surveillance schedules could be maintained; randomized studies comparing the various 320 
enhanced optical modalities are therefore urgently required. Similarly, CTU may permit upper 321 
tract surveillance intervals to be increased in some groups of patients, and further studies are 322 
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also needed 40. Furthermore, although existing commercial and FDA-approved urinary 323 
biomarkers do not have real clinical utility due to their relatively low sensitivities and 324 
specificities, the latest generation of research platforms show significant promise in the field of 325 
urinary biomarker discovery. 326 
Chemoprevention of NMIBC recurrence is a topic that remains outside the scope of current 327 
guidelines, although a number of such trials are currently in follow-up (e.g. BOXIT, SELENIB). 328 
Likewise, chemohyperthermia and electromotive drug administration may become important 329 
tools in the urologist’s armamentarium in the future.  330 
Office fulguration/ablation is not widely practiced by European urologists despite favourable 331 
evidence from the USA (probably due to provider/practice differences), although the 332 
technique appears safe, convenient and cost-effective 43,44. However, without biopsying the 333 
lesion beforehand we do not feel that we can recommend this as a universal approach to the 334 
management of recurrent tumors in patients previously/consistently diagnosed with low-risk 335 
TaBC outside of specialized bladder cancer practices, or unless determined by the frailty of the 336 
patient. Furthermore, in an era where genetic and epigenetic analyses on nanogram amounts 337 
of DNA are likely to yield considerable prognostic information, the importance of biopsy 338 
material is likely to appreciate significantly. Omission of a simple biopsy is thus likely to become 339 
an increasingly inappropriate approach in the cancer setting. 340 
341 
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CONCLUSIONS  342 
The traditional view that TaBC invariably represents low-risk disease requires re-evaluation: a 343 
significant number of patients will progress, and a number will die from their disease. Modern 344 
management of TaBC depends on initial risk stratification that allows subsequent management 345 
to be based on a number of evidence-based guidelines. Given the usually long clinical course for 346 
most patients with TaBC, patients often suffer many recurrences and are subjected to repeated 347 
surgical intervention. An evidence-based approach ensures not only safe but economical care of 348 
this group of patients. 349 
350 
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LEGEND FOR TABLES 483 
Table 1  484 
The costs of bladder cancer care, shown in Euros (taken from Svatek et al 6  with permission). 485 
BCG = bacillus Calmette-Guérin; MMC = mitomycin C; TURBT = transurethral resection of 486 
bladder tumour. *US Medicare rates.487 
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LEGEND FOR FIGURES 488 
Figure 1 489 
A flow-chart representing the management of NMIBC, demonstrating the differences between 490 
the AUA and EAU guidelines (w=weeks, m=months, y=years, CTU=CT urography) 10,16. Our views 491 
and interpretations are included in the dashed boxes.492 
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Table 1: 493 
 494 
 United 
States* 
United 
Kingdom 
Sweden Germany Italy 
Office cystoscopy 163 520 165 - - 
TURBT 4348 2362 2200 2500 2242 
Single dose of MMC 40mg 219 87 - - - 
BCG 6 weeks 528 630 - - 975 
Cystectomy 23451 8090 20570 15419 7222 
 495 
496 
34 
 
 
Figure 1: 497 
 498 
 499 
 500 
 501 
 502 
 503 
TURBT 
We suggest 
biopsy before 
fulguration 
(see text).  
Difficult to 
define a 
schedule for 
low- and 
intermediate-
risk; CTU 
preferred 
(see text). 
Intuitively, 
the most 
cost-effective 
schedule.  
We suggest 
minimum 10y 
follow-up for 
all risk 
categories 
(see text). 
EAU risk 
stratification 
AUA & EAU: Induction 
& maintenance BCG, 
1-3y. 
AUA & EAU:  
Re-TURBT  
(EAU: within 4-6w). 
AUA & EAU: Induction 
IVT, e.g. MMC or BCG  
(EAU: for 1y). 
ADJUVANT THERAPY 
AUA & EAU: “Single postoperative instillation of a chemotherapeutic agent  
(e.g. mitomycin C, MMC) in the immediate postoperative period”. 
High-risk  
TaBC 
Low-risk  
TaBC 
Intermediate-risk 
TaBC 
OR OR OR 
EAU: Cystoscopy & 
cytology 3m post-
TURBT, then every 3m 
for 2y if clear, then 
every 6m until 5y, 
then annually. 
EAU: In-between 
follow-up, using 
cystoscopy & 
cytology, adapted to 
personal & subjective 
factors. 
EAU: Cystoscopy 3m 
post-TURBT, then 9m 
later if clear, then 
annually for 5y. 
TREATMENT OF RECURRENCES  
EAU: TURBT, although “fulguration of small papillary recurrences on an 
outpatient basis could be a safe option that reduces the therapeutic burden”. 
AUA: No definitive guidance. 
OR 
EAU: Annual upper tract imaging with CTU or IVU for patients with high-risk 
tumors, or if cytology is positive in the absence of visible tumour. 
FOLLOW-UP 
AUA: “Patient assessment every three months in the first two years after initial 
diagnosis followed by every six months for the subsequent two to three years, 
and then annually thereafter”. 
UPPER TRACT SURVEILLANCE  
AUA: “Surveillance often includes periodic upper tract imaging, especially for 
high-risk patients”. 
